(From left) Choi Eun-seok, CEO of CJ CheilJedang, Cheon Jong-shik, CEO of CJ Bioscience, and Hwang Yun-il, CEO of CJ CheilJedang’s Bio Business Division, pose at the ‘CJ Bioscience Launch Ceremony’. Provided by CJ CheilJedang
CJ CheilJedang announced on the 5th that CJ Bioscience, a subsidiary specializing in red bio (pharmaceutical and healthcare), held a launching ceremony at CJ Human Resources Center in Jung-gu on the 4th and officially launched it.
CJ Bioscience is a subsidiary established by integrating ‘Chunlab’, a microbiome company that CJ CheilJedang acquired in October last year, and Red Bio Resources.
The term ‘microbiome’ is a combination of microbes and ecosystems, and refers to microorganisms and their genes that exist in the human body. Among them, by selecting the types that are helpful for health, their use in various fields such as medicines and health functional foods is increasing, and it is considered a market with great growth potential in the future.
Chun Jong-sik, new CEO of CJ Bioscience, said, “We will become a ‘global No. 1 microbiome company’ by possessing 10 pipelines (new drug candidates) and 2 technology exports by 2025.”
To this end, CJ Bioscience has secured super-gap R&D capabilities and accelerated the development of new drugs based on the Bio-Digital Platform. We are planning to expand our business area.
CEO Cheon said, “Within two to three years, we will promote the US Food and Drug Administration (FDA) clinical entry of new drug pipelines for the treatment of immuno-oncology and autoimmune diseases and export technology through joint research with large global pharmaceutical companies.” The OM-based bio platform technology will have a significant impact on the overall medical and healthcare fields, becoming a new global blockbuster such as immuno-oncology drugs and mRNA vaccines.”